舒眠膠囊聯合米氮平對抑郁癥伴失眠患者的影響

【摘要】 目的：研究分析舒眠膠囊聯合米氮平治療抑郁癥伴失眠患者的應用價值。方法：選擇包頭市第六醫院2020年6月—2022年3月收治的90例抑郁癥伴失眠患者作為本次研究對象，以隨機數字表法分為對照組和觀察組，每組45例。對照組患者接受米氮平治療，觀察組在對照組基礎上加用舒眠膠囊治療。對比兩組臨床治療效果、睡眠質量、抑郁情況、生活質量、不良反應。結果：觀察組臨床療效顯著高于對照組，差異有統計學意義（Plt;0.05）。治療后兩組漢密爾頓抑郁量表（HAMD-17）和匹茲堡睡眠質量指數（PSQI）評分均降低，生活質量指數（QL-I）評分均升高，觀察組HAMD-17和PSQI評分均低于對照組，QL-I評分高于對照組（Plt;0.05）。觀察組副反應量表（TESS）評分和不良反應發生率均高于對照組，但兩組比較，差異均無統計學意義（Pgt;0.05）。結論：針對抑郁癥伴失眠患者，應用舒眠膠囊聯合米氮平的治療方案的臨床效果理想，不僅抑郁癥狀得到緩解，其睡眠質量也得到了有效提高，且用藥安全性高。

【關鍵詞】 舒眠膠囊 米氮平 抑郁癥 失眠 生活質量

Effect of Shumian Capsules Combined with Mirtazapine on Patients with Depressive Disorder Complicated with Insomnia/WANG Juan， YANG Yiran. //Medical Innovation of China， 2023， 20（31）： 0-075

[Abstract] Objective： To study the application value of Shumian Capsules combined with Mirtazapine in the treatment of patients with depressive disorder complicated with insomnia. Method： A total of 90 patients with depressive disorder complicated with insomnia admitted to Baotou No.6 Hospital from June 2020 to March 2022 were selected as the objects of this study， and were divided into control group and observation group according to random number table method， with 45 cases in each group. Patients in the control group was treated with Mirtazapine， observation group was treated with Shumian Capsules on the basis of control group. The clinical treatment effect， sleep quality， depression situation， quality of life and adverse reactions were compared between the two groups. Result： The clinical efficacy of the observation group was significantly higher than that of the control group， the difference was statistically significant （Plt;0.05）. After treatment， the scores of Hamilton depression scale （HAMD-17） and Pittsburgh sleep quality index （PSQI） decreased in both groups， the scores of quality of life index （QL-I） increased in both groups， and the scores of HAMD-17 and PSQI in the observation group were lower than those in the control group， the scores of QL-I was higher than that in the control group （Plt;0.05）. Treatment emergent symptom scale （TESS） scores and incidence of adverse reactions in the observation group were higher than those in the control group， but there were no statistical significances between the two groups （Pgt;0.05）. Conclusion： For patients with with depressive disorder complicated insomnia， the clinical effect of Shumian Capsules combined with Mirtazapine is ideal， not only the symptoms of depression can be relieved， but also the sleep quality can be effectively improved， and the drug safety is high.

[Key words] Shumian Capsules Mirtazapine Depressive disorder Insomnia Quality of life

First-author's address： Baotou No.6 Hospital， Inner Mongolia， Baotou 014040， China

doi：10.3969/j.issn.1674-4985.2023.31.017

抑郁癥近年來具有較高的發病率，但現階段臨床尚未完全闡明其發病機制，認為其是由多種因素相互作用形成，包括遺傳、神經生化、心理變化、社會環境變化（工作壓力等）等[1]。抑郁癥作為一種常見的精神性障礙疾病，女性發病率高于男性，并且病情持續時間長，患者心情有明顯的落差感，表現出自責、過度難受等消極情緒，嚴重的可出現自殺、厭世的行為，同時因患者長期處于消極情緒狀態，會導致睡眠質量欠佳，如失眠等睡眠障礙，進而加重抑郁癥對患者身心健康及日常生活質量的不良影響[2]。……